PRKACA and hepatocellular carcinoma: Successful deletion was observed in 80% of the mice and resulted in a Dnajb1–Prkaca fusion mutation, which has been identified in 80–100% of patients with fibrolamellar hepatocellular carcinoma (FL-HCC), a rare form of liver cancer whose molecular basis is not established [219].